๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shijiazhuang
Clinical trial register · China

Clinical Trials in Shijiazhuang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Hebei Medical University Fourth Hospital43 Novartis Pharmaceuticals12 BeOne Medicines9 Beijing InnoCare Pharma Tech Co., Ltd.8 Bristol-Myers Squibb8
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shijiazhuang

341 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
NCT07219615Chronic Spontaneous Urticaria
Pfizer
Phase 2
200
Beijing, Guangzhou, Shijiazhuang, Shanghai, Tianjin, Hangzhou
2025-10-30
Recruiting
Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.
NCT07569653Cytomegalovirus Infections, Cytomegalovirus Disease, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease
WeiShi
Phase 4
120
Beijing, Shijiazhuang, Zhengzhou, Jingzhou, Wuhan, Hohhot, Nanchang, Wenzhou
2025-10-30
Recruiting
Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
NCT07469267Breast Cancer, Radiotherapy
Fudan University
Not applicable
1,608
Guiyang, Shijiazhuang, Harbin, Wuhan, Changde, Changsha, Dalian, Jinan
2025-10-24
Recruiting
Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)
NCT07272434Respiratory Syncytial Virus (RSV)
MAXVAX Biotechnology Limited Liability Company
Phase 3
25,000
Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Xi'an, Jinan, Chengdu
2025-10-22
Recruiting
Desflurane vs. Propofol for Cardiac Anesthesia
NCT07116733Cardiac Surgery, Coronary Artery Bypass Grafting
Xijing Hospital
Phase 3
3,560
Fuzhou, Cangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjin, Xi'an, Chengdu
2025-10-20
Recruiting
KD Treatment for Super-refractory Status Epilepticus
NCT07496749Super-refractory Status Epilepticus
Xuanwu Hospital, Beijing
Not applicable
84
Hefei, Beijing, Fuzhou, Nanning, Guiyang, Haikou, Shijiazhuang, Harbin
2025-10-20
Active, closed
Biomechanical Simulation Analysis of the Lower Extremity During Running in Males With Type A Lower Crossed Syndrome.
NCT07397143Lower Crossed Syndrome
Universiti Sains Malaysia
Not applicable
44
Shijiazhuang
2025-10-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
NCT07140913Mania, Bipolar Disorder
Bristol-Myers Squibb
Phase 3
424
Beijing, Guangzhou, Baoding, Shijiazhuang, Nanjing, Xi'an, Chengdu, Tianjin
2025-10-08
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S
Phase 3
1,280
Hefei, Beijing, Changchun, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Harbin
2025-10-02
Not yet open
Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
NCT07206264Mantle Cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
45
Fuzhou, Shijiazhuang, Harbin, Jinan, Tianjin
2025-10
Recruiting
Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
NCT07289997AFP Gastric or Gastroesophageal Junction Adenocarcinoma, PD-1/CTLA-4, AFPGC, Immunotherapy
Hebei Medical University Fourth Hospital
Phase 2
39
Shijiazhuang
2025-09-28
Recruiting
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
NCT07290010Esophageal Squamous Cell Carcinoma (ESCC)
Hebei Medical University Fourth Hospital
Phase 2
25
Shijiazhuang
2025-09-26
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967Plaque Psoriasis
Bristol-Myers Squibb
Phase 3
3,040
Bengbu, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin
2025-09-22
Recruiting
Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics
NCT07131007Malignant Neoplasm, Organ Damage
Hebei Medical University Fourth Hospital
Observational
2,000
Shijiazhuang
2025-09-15
Not yet open
A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis
NCT07146126Seasonal Allergic Rhinitis, SAR
Prime Gene Therapeutics Co., Ltd.
Phase 3
600
Beijing, Lanzhou, Baoding, Cangzhou, Langfang, Shijiazhuang, Daqing, Harbin
2025-09-15
Recruiting
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
NCT07492394Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2
60
Shijiazhuang
2025-09-12
Recruiting
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
NCT06824103Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease
Novartis Pharmaceuticals
Phase 4
50
Hefei, Guangzhou, Nanning, Guiyang, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2025-09-09
Recruiting
A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis
NCT07129382Plaque Psoriasis
Chipscreen Biosciences, Ltd.
Phase 1/2
220
Beijing, Chengde, Shijiazhuang, Shiyan, Jinan, Taiyuan, Xiโ€™an, Hangzhou
2025-09-08
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3
500
Beijing, Fuzhou, Lanzhou, Guangzhou, Jiangmen, Nanning, Guiyang, Shijiazhuang
2025-09-04
Not yet open
Phrenic Nerve Stimulation for Reducing Ventilation Duration in Acute Cerebral Infarction: A Multicenter Randomized Controlled Trial
NCT07133932Cerebral Infarction, Mechanical Ventilation, Acute Cerebrovascular Accident, Adult
Xuanwu Hospital, Beijing
Not applicable
590
Beijing, Shijiazhuang
2025-09-01
Recruiting
Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML
NCT07304232Allogeneic Hematopoietic Cell Transplantation (HCT), AML (Acute Myeloid Leukemia)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
134
Shijiazhuang, Harbin, Tianjin
2025-09-01
Recruiting
Clinical Multimodal Surveillance of Respiratory Syndrome Pathogens
NCT07694648Respiratory Tract Infections (RTI), Respiratory Syndrome, Acute, Severe, Acute Respiratory Infections (ARIs)
Huashan Hospital
Observational
2,398
Beijing, Guangzhou, Zhuhai, Shijiazhuang, Harbin, Jiamusi, Shangqiu, Zhengzhou
2025-09-01
Recruiting
Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.
NCT07266480Squamous Oesophageal Cancer
Hebei Medical University Fourth Hospital
Phase 2
142
Shijiazhuang
2025-09-01
Not yet open
The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
NCT07139587Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Qingxia Li
Not applicable
30
Shijiazhuang
2025-09
Not yet open
A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors
NCT07185893Solid Tumor Malignancies, Cancer, CTIT-Chemotherapy Induced Thrombocytopenia, Thrombocytopenia
Jun wang
Not applicable
106
Shijiazhuang
2025-09
Recruiting
Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke
NCT07095790Mild Stroke
Second Affiliated Hospital of Soochow University
Phase 4
580
Suzhou, Shijiazhuang, Zhoukou, Bayan Nur, Huai'an, Suqian, Taizhou, Xi'an
2025-08-30
Recruiting
A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
NCT07110571Gastric Cancer, Gastroesophageal-junction Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
200
Shijiazhuang, Hangzhou
2025-08-28
Recruiting
LineMatrixยฎ Biological Vascular Graft for the Creation of Arteriovenous Graft
NCT07773051Arteriovenous Graft
Longhua Hospital
Not applicable
326
Beijing, Chongqing, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Nanchang
2025-08-25
Recruiting
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
NCT07023315Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Akeso
Phase 3
760
Beijing, Fuzhou, Shijiazhuang, Harbin, Shanghai, Tianjin
2025-08-14
Recruiting
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318Immune Thrombocytopenic Purpura (ITP)
Takeda
Phase 3
150
Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang
2025-08-14
Not yet open
A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
NCT07112833Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
Phase 2
36
Shijiazhuang
2025-08-10
Recruiting
Effectiveness of an AI-Enabled Stratified Management System for Premature Coronary Artery Disease
NCT07031531Premature Coronary Heart Disease
China National Center for Cardiovascular Diseases
Not applicable
4,900
Hefei, Beijing, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Nanjing, Yangzhou
2025-08-08
Recruiting
Discontinuation of Anticoagulation With Intensive Rhythm Monitoring in Post-ablation Patients With Atrial Fibrillation
NCT06871228Atrial Fibrillation (AF)
Beijing Anzhen Hospital
Not applicable
4,100
Hefei, Beijing, Guangzhou, Shijiazhuang, Harbin, Luohe, Zhengzhou, Wuhan
2025-08-05
Recruiting
Safety and Effectiveness of A Novel Continuous Glucose and Ketone Monitoring System
NCT07139808Type1diabetes
Henan University of Science and Technology
Not applicable
12
Shijiazhuang, Luoyang
2025-08-01
Recruiting
Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke
NCT07047014Stroke, Ischemic, Medium Vessel Occlusions
Beijing Tiantan Hospital
Phase 3
596
Beijing, Jiuquan, Shijiazhuang, Jiyuan, Lingbao, Nantong, Hangzhou
2025-07-30
Recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Amgen
Phase 3
12,800
Bengbu, Beijing, Guangzhou, Huizhou, Yulin, Qinhuangdao, Shijiazhuang, Harbin
2025-07-25
Recruiting
A Multi-center Cohort Study of Hydatidiform Mole in China (CN-HM-01)
NCT07202728Hydatidiform Mole
Obstetrics & Gynecology Hospital of Fudan University
Observational
1,489
Lanzhou, Shenzhen, Haikou, Shijiazhuang, Zhengzhou, Dalian, Shenyang, Jinan
2025-07-09
Not yet open
Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study
NCT07004335PD-(L)1, CTLA-4, Advanced Melanoma, Iparomlimab
Hebei Medical University Fourth Hospital
Phase 4
40
Shijiazhuang
2025-07-01
Not yet open
BR Combined With OR in Treatment-naรฏve Marginal Zone Lymphoma
NCT07008053Marginal Zone Lymphomas
Tianjin Medical University Cancer Institute and Hospital
Phase 2
37
Fuzhou, Shijiazhuang, Changsha, Jinan, Qingdao, Tianjin
2025-07
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
Amgen
Phase 3
5,056
Hefei, Beijing, Guangzhou, Haikou, Qinhuangdao, Shijiazhuang, Harbin, Kaifeng
2025-06-25
Active, closed
A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes
NCT07026968Type 2 Diabetes
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3
815
Shijiazhuang
2025-06-20
Recruiting
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
NCT06991257Heart Failure
Pfizer
Phase 2
620
Beijing, Lanzhou, Guangzhou, Haikou, Shijiazhuang, Changsha, Changchun, Xi'an
2025-06-19
Recruiting
Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection
NCT07434063Neutropenia
Hebei Medical University Fourth Hospital
Observational
200
Shijiazhuang
2025-06-18
Active, closed
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744Ulcerative Colitis
AbbVie
Phase 3
573
Hefei, Beijing, Chongqing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2025-06-17
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3
630
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Shijiazhuang, Harbin
2025-06-11
Recruiting
A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China
NCT06931691Paroxysmal Nocturnal Hemoglobinuria
Novartis Pharmaceuticals
Observational
80
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nantong, Nanchang, Changchun
2025-06-10
Recruiting
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
NCT06962839Macular Edema
Boehringer Ingelheim
Phase 2
300
Chengdu, Shanghai, Shenyang, Shijiazhuang, Taiyuan
2025-06-05
Active, closed
Partial Rotator Cuff Injury Combined With Stiff Shoulder
NCT07192302Rotator Cuff Tears of the Shoulder, Shoulder Adhesive Capsulitis, Shoulder Arthroscopy
Hebei Medical University Third Hospital
Phase 1
80
Shijiazhuang
2025-06-01
Recruiting
The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
NCT07002112Relapsed/Refractory B-cell Malignancies
The First Affiliated Hospital with Nanjing Medical University
Phase 1
30
Hefei, Beijing, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2025-05-23
Recruiting
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer๏ผˆNeo-Color๏ผ‰
NCT06949111Colon Cancer
Hebei Medical University Fourth Hospital
Phase 2
128
Shijiazhuang
2025-05-15
Recruiting
Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer
NCT06949098Rectal Cancer Stage I
Hebei Medical University Fourth Hospital
Phase 2
60
Shijiazhuang
2025-05-15
Recruiting
ICP-332 in Subjects With Non-segmental Vitiligo
NCT07047612Non Segmental Vitiligo
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3
603
Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Luoyang, Nanyang
2025-05-09
Recruiting
Clinical Trials of Quadrivalent Influenza Vaccine
NCT06824519Influenza, Human
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Phase 1/2
620
Shijiazhuang
2025-05-08
Recruiting
Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads
NCT06947356Hepatitis B
Guangzhou 8th People's Hospital
Not applicable
210
Guangzhou, Shenzhen, Shijiazhuang, Changsha, Wenzhou, Beijing
2025-05-03
Recruiting
LIRRH Trial for the Right-sided Colon Cancer
NCT07207317Ascending Colon Cancer, Proximal Transverse Colon Cancer
Chaoxi Zhou
Not applicable
120
Shijiazhuang
2025-05-01
Not yet open
A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis
NCT06958861Acute Exacerbations of Bronchiectasis
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 2
180
Fuyang, Hefei, Fuzhou, Guangzhou, Shenzhen, Baise City, Shijiazhuang, Nanyang
2025-05
Recruiting
Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines
NCT06937944Moderate to Severe Glabellar Lines
JHM BioPharma (Tonghua) Co. , Ltd.
Phase 3
669
Beijing, Chongqing, Guangzhou, Shijiazhuang, Changsha, Xuzhou, Shanghai, Xianyang
2025-04-30
Recruiting
Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy
NCT06817265Non-Proliferative Diabetic Retinopathy
Beletalent (Zhuhai) Pharmaceutical Co., Ltd
Phase 3
360
Xuancheng, Beijing, Guangzhou, Shenzhen, Zhuhai, Guiyang, Shijiazhuang, Kaifeng
2025-04-29
Recruiting
Efficacy and Safety of Catheter abLation in patiEnts With seVere mitrAl regurgiTation and pErsistent Atrial Fibrillation: a Randomized Controlled Trial
NCT06883864Atrial Fibrillation (AF), Catheter Ablation, Atrial Functional Mitral Regurgitation
Beijing Anzhen Hospital
Not applicable
146
Hefei, Beijing, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2025-04-08
Not yet open
Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)
NCT06903871Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III
Hebei Medical University Fourth Hospital
Phase 2
190
Shijiazhuang
2025-04-01
Not yet open
Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors
NCT06929325HR+/HER2- Advanced/Metastatic Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3
312
Shijiazhuang
2025-04
Recruiting
The Effect of VitC on IVF Outcome of DOR Patients
NCT06794047Diminished Ovarian Reserve, IVF Outcomes
Peking University Third Hospital
Not applicable
1,100
Beijing, Shijiazhuang, Yinchuan, Xiโ€™an, Shenzhen
2025-03-17
Recruiting
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
NCT06854445Diffuse Large Cell B-lymphoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
55
Wuhu, Xiamen, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Zhengzhou
2025-03-12
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466Menstrual Migraine
Pfizer
Phase 3
723
Beijing, Chongqing, Shijiazhuang, Nanjing, Suzhou, Xi'an, Xianyang, Shanghai
2025-03-11
Not yet open
Inflammatory and Metabolic Prognostic Assessment in Critically Ill Neurological Patients
NCT06849011Stroke Acute, Encephalitis, Non-traumatic Brain Injury
Yan Zhang
Observational
1,185
Beijing, Lanzhou, Guiyang, Zunyi, Tangshan, Shijiazhuang, Hohhot, Suzhou
2025-03-01
Not yet open
Tislelizumab in Combination with Chemotherapy ยฑ Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer.
NCT06851819Small Cell Lung Cancer Extensive Stage
Hebei Medical University Fourth Hospital
Phase 2
64
Shijiazhuang
2025-03-01
Recruiting
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
NCT07179900Hepatocellular Carcinoma
Hebei Medical University Fourth Hospital
Phase 2
60
Shijiazhuang
2025-03-01
Recruiting
A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome
NCT06696261Postprandial Distress Syndrome
Tasly Pharmaceutical Group Co., Ltd
Phase 3
342
Beijing, Lanzhou, Guiyang, Shijiazhuang, Xingtai, Baoding, Luoyang, Changchun
2025-02-27
Recruiting
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235Immune Thrombocytopenic Purpura (ITP)
Takeda
Phase 3
171
Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang
2025-02-27
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Beijing, Shenyang, Shijiazhuang, Guangzhou, Changsha, Jinan, Jining, Shanghai
2025-02-26
Recruiting
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
NCT06797297Melanoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
180
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2025-02-24
Recruiting
Modified Tumor-free Techniques Operation to Cervical Cancer
NCT06836869Cervical Cancer Stage IB2
Peking Union Medical College Hospital
Not applicable
524
Lanzhou, Guangzhou, Cangzhou, Shijiazhuang, Changsha, Changchun, Shanghai, Xianyang
2025-02-20
Active, closed
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293Menstrual Migraine (MM)
AbbVie
Phase 3
468
Beijing, Guangzhou, Shijiazhuang, Wuhan, Suzhou, Xi'an, Taiyuan, Tianjin
2025-02-10
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920Generalized Myasthenia Gravis
Novartis Pharmaceuticals
Phase 3
180
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Wuxi, Changchun, Beijing
2025-02-07
Active, closed
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjรถgren's Syndrome
NCT06684847Primary Sjogrens Disease
argenx
Phase 3
631
Bengbu, Hefei, Guangzhou, Nanning, Guiyang, Shijiazhuang, Luoyang, Xinxiang
2025-01-15
Recruiting
A Study to Evaluate the Accuracy of aTCI Model of Cipepofol in Patients With General Anesthesia During Elective Surgery
NCT06740201Anesthesia
Haisco Pharmaceutical Group Co., Ltd.
Phase 4
40
Chengde, Shijiazhuang
2025-01-06
Recruiting
Multimodal Deep Learning for Lymph Node Metastasis Prediction and Physician Performance Assessment in T1 Gastric Cancer
NCT07124754T1 Gastric Cancer Lymph Node Metastasis Early Gastric Cancer Artificial Intelligence-Assisted Diagnosis Multimodal Data Integration
Qun Zhao
Observational
300
Shijiazhuang
2025-01-01
Recruiting
Assessment of the Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients With Major Depressive Disorder
NCT06692361Major Depressive Disorder (MDD), Depression - Major Depressive Disorder
Gang Wang
Not applicable
214
Wuhu, Beijing, Guangzhou, Shijiazhuang, Jining, Chengdu, Tianjin, Dali
2025-01-01
By invitation
Radiomics-Based AI Model for Predicting Para-Aortic Lymph Node Metastasis in Gastric Cancer Patients
NCT06947096Gastric Cancer, Para-Aortic Lymph Node Metastasis, Lymphatic Metastasis, Preoperative Imaging Assessment
Qun Zhao
Observational
120
Shijiazhuang
2025-01-01
Not yet open
Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia
NCT06643195AML
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
358
Shijiazhuang, Zhengzhou, Jinan, Chengdu
2025-01-01
By invitation
AI-Based Prediction of Lymph Node Metastasis in Gastric Cancer Using Preoperative Multimodal Data
NCT06957678Gastric Cancer Adenocarcinoma Metastatic, Lymph Node Metastasis, Artificial Intelligence (AI) in Diagnosis
Qun Zhao
Observational
1,200
Shijiazhuang
2025-01-01
Recruiting
Efficacy and Influencing Factors of ALIC-NAc Deep Brain Stimulation in Treatment-Refractory Obsessive-Compulsive Disorder
NCT07031544Obsessive - Compulsive Disorder
Shanghai Mental Health Center
Not applicable
60
Guangzhou, Shijiazhuang, Xinxiang, Nanchang, Taiyuan, Mianyang, Shanghai, Tianjin
2024-12-14
Recruiting
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
NCT06625593Advanced Solid Tumor
BeOne Medicines
Phase 1
168
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Nanning, Shijiazhuang, Harbin
2024-12-09
Active, closed
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis๏ผšBDLL Chinese Cohort
NCT06649721Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis
Huashan Hospital
Phase 3
120
Hefei, Beijing, Xiamen, Nanning, Liupanshui, Shijiazhuang, Harbin, Jiamusi
2024-11-27
Recruiting
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
NCT06564324Non Small Cell Lung Cancer
Nuvation Bio Inc.
Phase 3
194
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Zhengzhou
2024-11-27
Recruiting
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
NCT06568471Hypercholesterolemia, Dyslipidemias, Primary Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
Hasten Biopharmaceutical Co., Ltd.
Phase 3
210
Beijing, Guangzhou, Shijiazhuang, Daqing, Changsha, Nanchang, Binzhou, Heze
2024-11-16
Active, closed
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
NCT06576921Stomach Neoplasms, Immune Checkpoint Inhibitors
Xijing Hospital
Phase 2
116
Shijiazhuang, Xi'an, Tianjin
2024-11-15
Recruiting
A Phase 2 Clinical Study of ABSK061 and ABSK043
NCT06632262HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
Abbisko Therapeutics Co, Ltd
Phase 2
202
Guiyang, Shijiazhuang, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Jinan
2024-11-13
Not yet open
Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)
NCT06681285Esophageal Carcinoma
Hebei Medical University Fourth Hospital
Phase 2
51
Shijiazhuang
2024-11-01
Not yet open
Levothyroxine Intervention in Pregnant Women with TSH ๏ผˆ2.5 MIU/L-upper Limit of Reference Range๏ผ‰ and Negative Thyroid Peroxidase Antibody
NCT06653907Thyroid Abnormalities, Pregnant Woman, Pregnancy Outcomes
Yang ZHANG
Phase 4
400
Shijiazhuang
2024-10-25
Recruiting
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
NCT06598800Advanced Solid Tumor
BeOne Medicines
Phase 1
153
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-10-18
Not yet open
Twice-per-weekSelinexor, 2 Days Melphalan
NCT06613035Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
126
Shijiazhuang, Zhengzhou, Jinan, Chengdu
2024-09-30
Not yet open
A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight
NCT06606483Obesity, Overweight and Obesity
MindRank AI Ltd
Phase 2
300
Hefei, Xuancheng, Zibo, Beijing, Haikou, Shijiazhuang, Harbin, Luoyang
2024-09-23
Active, closed
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
NCT06559163Systemic Lupus Erythematosus
Zenas BioPharma (USA), LLC
Phase 2
190
Hefei, Beijing, Guangzhou, Shenzhen, Shijiazhuang, Nanchang, Pudong, Shanghai
2024-09-17
Recruiting
Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer
NCT05578053Breast Cancer
Hebei Medical University Fourth Hospital
Observational
420
Shijiazhuang
2024-09-13
Recruiting
Efficacy and Safety of SR1375 in Adult Patients With CAP
NCT06577558Community-acquired Pneumonia
Shanghai SIMR Biotechnology Co., Ltd.
Phase 2
240
Fuyang, Beijing, Zhangzhou, Gaozhou, Guangzhou, Shantou, Yulin, Shijiazhuang
2024-09-10
Active, closed
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076Plaque Psoriasis
Takeda
Phase 3
2,099
Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Zhenjiang, Shanghai
2024-09-04
Active, closed
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06508658Diffuse Large B-Cell Lymphoma
Genmab
Phase 3
379
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2024-08-13
Active, closed
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Novartis Pharmaceuticals
Phase 2
84
Shijiazhuang, Zhengzhou, Beijing
2024-08-05
Recruiting
Construction and Application of Database of Hebei Provincial Gastric Cancer Collaborative Network Driven by Artificial Intelligence Technology
NCT06506825The Study Focuses on Gastric Cancer
Qun Zhao
Observational
30,000
Shijiazhuang
2024-08-01
Rows per page Showing 101–200 of 341
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/shijiazhuang?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 341 of those studies with a site in Shijiazhuang.

How many clinical trials are recruiting in Shijiazhuang?

209 of the 341 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 52 have not yet opened recruitment, 75 are active but closed to new participants, and 5 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.